Statin-based hyperlipidemia treatment
Launch of ‘Atroban Tablet’
In October, KyungDong Pharm Co., Ltd. plans to release ‘Atroban Tablet’, a statin-based hyperlipidemia treatment. ‘Atroban Tablet’ is a hyperlipidemia treatment that contains atorvastatin calcium 10.85mg (10mg as atorvastatin) and is the only statin drug with established safety for children aged 10 to 17.
In addition, compared to other statin drugs, it shows a strong LDL-C lowering effect based on the same dose, and all patients can expect a rapid treatment effect by quickly reaching the LDL-C target level.
Compared to simvastatin, it has a stronger lipid profile improvement effect, so it has an excellent cardiovascular disease prevention effect by reducing the frequency of cardiovascular disease and the risk of myocardial infarction and stroke in diabetic patients.
With the release of ‘Atroban Tablets’, which are convenient to take and have excellent safety, we can expect good results in the treatment of hyperlipidemia.
◈ Ingredient content: Atorvastatin 10mg
◈ Effectiveness
▷ Reduced risk of myocardial infarction, vascular revascularization, and chronic stable angina in adult patients with multiple risk factors for coronary artery disease.
▷ Reduced risk of myocardial infarction and stroke in type 2 diabetes patients with multiple risk factors for coronary heart disease
▷ Dietary supplement for reducing elevated TC, TG, LDL-C, and ALP-B levels in patients with primary hypercholesterolemia and mixed dyslipidemia
▷ Dietary supplement for patients with elevated serum TG
▷ Primary dysbetalipoproteinemia that does not respond to diet therapy
◈ Dosage: Initial dose is 10mg once a day, maximum 80mg per day
◈ Appearance: White, oval film-coated tablet
◈ Insurance price: 612 won/T
◈ Claim code: A17605001
◈ Packaging unit: 30, 100T
※ Please refer to the product manual for usage precautions and other detailed information.